AJN003 (LuCI™)
Type 2 Diabetes
Pre-clinicalAdvancing to Phase 1 (planned 2026)
Key Facts
About AltrixBio
AltrixBio is pioneering a new category of metabolic therapeutics with its lead candidate, AJN003, a once-daily oral pill that mimics the distal nutrient shift of gastric bypass surgery. Founded by a team with deep clinical and scientific expertise, the company leverages a bio-engineered compound derived from sucralfate, aiming to deliver glycemic control and weight loss without systemic absorption. With strong pre-clinical data, a clear regulatory strategy, and a platform with potential applications beyond diabetes, AltrixBio is positioned to address significant unmet needs in the growing obesity and metabolic disease markets.
View full company profileTherapeutic Areas
Other Type 2 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| Diabetes Management Gel | Gelteq Limited | Formulation Development |
| Tolimidone | Biodexa Pharmaceuticals | Phase 2 |
| Generic Semaglutide Injection (Obeda) | Dr. Reddy's Laboratories | Approved |
| BioChaperone® Lispro | Adocia | Phase 3 |
| BioChaperone® Combo (Insulin Glargine / Lixisenatide) | Adocia | Phase 2 |
| Metformin API | USV Biologics Division | Commercial |
| Empagliflozin | Azico Biophore | Commercial |
| Sitagliptin Intermediate | AR Life Science | Commercial |
| Sitagliptin Phosphate Polymorph | Morepen Laboratories | Pre‑clinical |
| Hepatic Denervation for Type 2 Diabetes | Metavention | Feasibility |
| MVD-1 (SANA) | Eolo Pharma | Discovery |
| Type 2 Diabetes Management | iWel | Development |